TP53 and acute myeloid leukemia: However, although AML is, overall, a heterogeneous disease, surprisingly more than 90% of de novo AML retain wild-type TP532,3, suggesting that human AML subtypes employ alternative mechanisms to inactivate the p53 pathway5.